ライフサイエンスコーパス: blood donor

1 lood count [CBC]), and 102 controls (healthy blood donors).

2 ftment after a second transfer from the same blood donor.

3 atched unrelated donor or 6/6 unrelated cord blood donor.

4 ified the 25P13 antibody from an independent blood donor.

5 ls in communities and 721 (13.0%, 12.1-13.9) blood donors.

6 patitis C virus epitope in a random group of blood donors.

7 d Kingdom and Vietnam and from 26 healthy US blood donors.

8 identify 16 invariant TCRs shared among many blood donors.

9 V RNA-negative plasma and PBMCs from healthy blood donors.

10 Controls comprised healthy blood donors.

11 n a control group of 41 age- and sex-matched blood donors.

12 rroborating with those obtained from healthy blood donors.

13 anti-PEG antibodies in a quarter of healthy blood donors.

14 f antibody responses in 370 WNV-seropositive blood donors.

15 patients with IBD and 112 healthy unrelated blood donors.

16 ith CD, 25 patients with UC and 45 controls, blood donors.

17 widespread in the English population and in blood donors.

18 rica were firstly identified amongst Chinese blood donors.

19 to be damaging and not found among 185 local blood donors.

20 e unequivocal identification of Vel-negative blood donors.

21 tients with osteomyelitis and in 299 matched blood donors.

22 ich were coinfected with HCV, and 54 healthy blood donors.

23 nfected or HIV-1/HCV coinfected patients, or blood donors.

24 recently infected vs more remotely infected blood donors.

25 ors and discrepancies between facilities and blood donors.

26 by blood centers to improve safety for young blood donors.

27 ymorphism (SNP) profile of healthy AA and EA blood donors.

28 d with only 3 of 44 (6.8%) healthy volunteer blood donors.

29 rols were derived from 1280 northern English blood donors.

30 be assessed by follow-up studies of viremic blood donors.

31 lidation, we analyzed plasma samples from 79 blood donors.

32 ng and molecular surveillance of HIV-1 among blood donors.

33 ro generated monocyte-derived DCs of healthy blood donors.

34 ute zoster and in 9% of healthy asymptomatic blood donors.

35 ith neurologic symptoms and 44% of voluntary blood donors.

36 screening of plasma samples from individual blood donors.

37 exposure to the virus in many indeterminate blood donors.

38 es 1, 2, and 5 in samples from South African blood donors.

39 arable controls, but greater than in healthy blood donors.

40 to WNV and to identify potentially infected blood donors.

41 blood mononuclear cells (PBMCs) from healthy blood donors.

42 er among tissue donors than among first-time blood donors.

43 d 5 with arthritis), and sera from 20 normal blood donors.

44 ined by testing 999 specimens from volunteer blood donors.

45 a VWF was studied in a series of 541 healthy blood donors.

46 mong 583 MSM and 583 age-matched repeat male blood donors.

47 e novo TSA developed against 150/244 (61.5%) blood donors.

48 nsity score matching with a series of female blood donors.

49 smatched unrelated, haploidentical, and cord blood donors.

50 emaining components and serum specimens from blood donors.

51 CRC patients was compared with 5270 healthy blood donors.

52 was detected in peripheral blood of healthy blood donors.

53 and hepatitis C seroprevalence trends among blood donors.

54 loped for race differentiation of peripheral blood donors.

55 munities and 5559 (81.4%, 80.4-82.3) of 6832 blood donors.

56 5%), ischemic heart failure (2%), or healthy blood donors (0.3%).

57 ence interval [95% CI], 0.0025 to 0.007) for blood donors, 0.86 (95% CI, 0.02 to 0.71) for VA patient

58 nd May 3, 2016, 20 757 of the 38 035 invited blood donors (10 843 [58%] men, 9914 [51%] women) partic

59 ietic-cell transplant from an unrelated cord-blood donor (140 patients), an HLA-matched unrelated don

60 disease (n = 106) and 2 control groups (198 blood donors, 151 patients with Crohn's disease) were an

61 We prospectively recalled 363 past blood donors (180 who were rapid screen assay [RSA] posi

62 selected comparative group of United Kingdom blood donors (2.5 x 10(5) versus 2.9 x 10(6) IU/ml; P =

63 1%), ischemic heart failure (1%), or healthy blood donors (2.5%; P=0.0001).

64 tients with early RA, 2 (2.7%) of 73 healthy blood donors, 2 (2.1%) of 94 individuals with osteoarthr

65 45 263 whole blood donors (22 466 men, 22 797 women) were recruited b

66 as 20%-significantly higher than that of 177 blood donors (5.1%; P=.001; OR, 4.67; 95% CI, 1.91-11.65

67 HV-8 seroprevalence was 2.8% (29/1023) among blood donors, 7.1% (96/1350) among transfusion recipient

68 years or older) and active (age 17-69 years) blood donors, adjusted seroprevalences were 1.4% (95% CI

69 The effect of blood donor adverse events on donor retention rates is a

70 ive kidney transplant recipients and healthy blood donors after stimulation of peripheral blood monon

71 ELISpot frequencies from healthy HPV-exposed blood donors against HLA-A*0201-binding peptides were un

72 bodies (Wantai) and compared to 1,110 active blood donors age 17-69 years.

73 We identified 60,926 retired blood donors age 70 years or older in the rosters of thr

74 gmatic, randomised trial, we recruited whole blood donors aged 18 years or older from 25 centres acro

75 , pragmatic, randomised trial that recruited blood donors aged 18 years or older from 25 static donor

76 asles seroprevalence survey of 508 Minnesota blood donors aged 20-39 years was conducted; 91% had ser

77 to infection, from a single sample of 1,936 blood donors aged 20-70 years in mainland France in June

78 initially asymptomatic T cruzi-seropositive blood donors, although disease was mild at diagnosis.

79 efficacy, we conducted a linked analysis of blood donor and component data with patients who receive

80 Mononuclear cells from 56 blood donors and 10 livers that were not suitable for tr

81 ggregated IgG (H-IgG) (control) in 15 normal blood donors and 16 RA patients not receiving immunosupp

82 nses against clinically relevant TAAs in 114 blood donors and 44 women during their first pregnancy.

83 As healthy controls 160 adult blood donors and 65 children were included.

84 on of HLA antibodies in plasma of implicated blood donors and a combination of the granulocyte agglut

85 Arg296 was found in 6 other primates, > 250 blood donors and A(pae) family relatives without the A(p

86 ssed SARS-CoV-2 seroprevalence among retired blood donors and combined it with national COVID-19 surv

87 A review of blood donors and follow-up testing identified one donor

88 tested serum and plasma samples from healthy blood donors and from patients with blood cultures posit

89 quencing analysis in 26 libraries from three blood donors and negative controls.

90 nes from HLA-A*0201-positive (HLA-A*0201(+)) blood donors and patients with myeloma.

91 il-specific antibodies in the plasma of both blood donors and recipients have been implicated in the

92 Unrelated non-cord-blood donors and recipients were typed at the allelic le

93 newly generated viral genome sequences from blood donors and recipients, we assess the dynamics of d

94 dengue RNA detection period in asymptomatic blood donors and relationships between donor viremia and

95 ositive (30 with HTLV-I and 55 with HTLV-II) blood donors and their stable (>or=6 months) heterosexua

96 antly elevated in ICU patients compared with blood donors and were the highest in septic patients.

97 West Nile fever, 17 West Nile virus-positive blood donors, and 19 deaths in 2012.

98 region located in SMIM1 intron 2 in Swedish blood donors, and observed a strong correlation between

99 , determinants and importance of low iron in blood donors, and on the efforts to reduce or prevent ir

100 ed from naive T cells, purified from healthy blood donors, and reactivated in the presence of IL-1bet

101 celiac disease patients' sera versus normal blood donors, and their conformational features were eva

102 Among 653 healthy volunteers, blood donors, and women on delivery, high-titered HLA-A*

103 One in 200 blood donors are heterozygous for the TACI A181E mutatio

104 Blood donors are routinely screened for hepatitis C viru

105 cer) study (July 2008-October 2012) plus 312 blood donors as healthy participants.

106 mary human macrophages derived from the same blood donors as the monocytes.

107 performed a large, cross-sectional study of blood donors at 6 US blood centers during 2006-2007.

108 ge-scale genotyping for HNA-3a/b to identify blood donors at risk to have HNA-3a-specific antibodies

109 The test was also offered to potential blood donors attending the central hospital in the capit

110 ion of genetic and epidemiological data from blood donor banks may be useful to anticipate epidemic s

111 establishing a 100% voluntary nonremunerated blood donor base and implementing component therapy.

112 PBMCs from 2 healthy HCV-negative blood donors became HCV RNA positive, with B-cell predom

113 tained intermittently from healthy HLA-typed blood donors between 1999 and 2012, we were able to demo

114 lar, and WHO reports using the search terms "blood donor", "blood donation","blood safety", "blood ba

115 Animal and human studies suggest that blood donor, blood product, and transfusion recipient va

116 lood donor spleen inoculum compared with the blood donor brain inoculum, suggesting lower titres of i

117 ear cells were isolated from 27 non-selected blood donor buffy coats, and ILCs were sorted by FACS.

118 ntenatal clinic groups, 1.99% (1.86-2.12) in blood donors, but 6.9% (6.1-7.5) in other general popula

119 HTLV-2 are prevalent at low levels among US blood donors, but recent data on their prevalence is lac

120 sis, 53 uninfected surgical patients, and 16 blood donors by using ddPCR.

121 positive and 328 HTLV-II-seropositive former blood donors, by use of real-time polymerase chain react

122 ted through large-scale routine screening of blood donors can complement molecular surveillance studi

123 Although the risk to blood donors cannot be eliminated, a systematic approach

124 ate that a significant percentage of healthy blood donors carry Chlamydia pneumoniae in their blood.

125 atic advances in blood banking in the 1970s, blood donor centers began supplying hospitals with indiv

126 recipients' marrow function was normal, and blood-donor chimerism levels were 97% to 100%.

127 gically suppressed patients or to 13 healthy blood donors, circulating CD141 (BDCA-3)(+) and CD1c (BD

128 and 1996 and in fresh PBMCs from 19 healthy blood donors collected in 2002 to 2003.

129 and injury occurs among 16- and 17-year-old blood donors compared with older donors.

130 with newly diagnosed type 1 diabetes and 50 blood donor control subjects, together with the WHO refe

131 derived from data on 200 RA patients and 98 blood donor controls, in which positivity for >/=9 ACPAs

132 nts with chronic HCV infection or uninfected blood donors (controls); NK cells and monocytes were iso

133 Using American Red Cross blood donor data as an example, the authors found that i

134 electronic health records (EHRs) and linked blood donor data.

135 evised guidance that recommended a change in blood donor deferral of men who have sex with men (MSM)

136 Collectively, blood donor demographic characteristics, collection and

137 This study describes changes in blood donor demographics and seroreactivity after testin

138 Of 39 134 recruited blood donors, DENV-4 viremia was confirmed in 0.51% of d

139 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig were obtained by HPLC and

140 ailable self-Ag and the genetics of the cord blood donor dictate the levels of central tolerance and

141 An understanding of characteristics of blood donors donating in times of crisis may help predic

142 pitation studies in macrophages from control blood donors (donor) and patients with either FPN1 p.A77

143 the French West Indies and 72 controls were blood donors during the same period, chikungunya infecti

144 ppressive activity ex vivo as 54% of healthy blood donors examined had fully suppressive Tregs sponta

145 reported that approximately 5-10% of normal blood donors express abnormally high or low levels of A

146 Testing of blood donors for human immunodeficiency virus type 1 (HI

147 Policies recommend screening blood donors for malaria, but none of the commonly used

148 tests of "minipools" of 16 samples to screen blood donors for West Nile virus RNA began in July 2003.

149 ), extracted from the plasma of thousands of blood donors, for removing HLA antibodies (Abs) in highl

150 ed, HCV antibody-positive (HCV+), allogeneic blood donors from 1991 to 2002 and 10,259 HCV antibody-n

151 e level of antibody reactivity among healthy blood donors from 2 widely separated regions of the Unit

152 ropositive, and 799 HTLV-seronegative former blood donors from 5 U.S. blood centers for a median of 1

153 The study of 61 HBV carrier blood donors from Lebanon revealed multiple patterns of

154 from a total of 600 American Red Cross adult blood donors from six locations in 2010.

155 IgA-deficient individuals than among healthy blood donors (GMT, 90.9) (P < 0.0001).

156 Only 40 (24%) of 165 relatives of blood donors had been tested.

157 Cord-blood donors had normal alpha-L-iduronidase activity (me

158 No Babesia test for screening blood donors has been licensed.

159 in donated blood, but no systematic study of blood donors has been reported.

160 The HTLV-1 and HTLV-2 prevalences among US blood donors has declined since the early 1990s.

161 ught to affirm that T. cruzi-seropositive US blood donors have persistent infection with demonstrable

162 ients (UGT1A1*28 homozygous) and 249 healthy blood donors (HBD) were genotyped for UGT1A (UGT1A1*28,

163 Compared to blood donors, human herpesviruses were more prevalent in

164 tcome of infection among 115 WNV-positive US blood donors identified in 2008-2011.

165 comparing CCR5Delta32 distribution among US blood donors identified through a comprehensive blood su

166 Nile virus (WNV) infection, acutely viremic blood donors, identified by nucleic acid amplification t

167 we utilized samples collected from volunteer blood donors in 17 provinces and municipalities.

168 active, 18- to 45-year-old, male, first-time blood donors in 6 US locations were tested for emtricita

169 Data on all first-time blood donors in a large network of US blood centers were

170 eptides in 81% of HIV-1- or HIV-1/2-infected blood donors in Abidjan, Cote d'Ivoire.

171 en analyzed with cells from EBV-seronegative blood donors in culture.

172 Blood donors in Denmark and Sweden between 1987 and 2012

173 on-respiratory indications and 0.1% in 1,000 blood donors in early April 2020.

174 ce of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April-June 2020.

175 h malaria parasites are commonly detected in blood donors in malaria-endemic areas, transfusion-trans

176 In human blood donors in Nicaragua, we observed a striking domina

177 data were compared with those of first-time blood donors in order to generate estimated incidence ra

178 ucing the antibody negative window period in blood donors in resource limited settings where nucleic

179 less frequent (2 of 14 patients [14.2%]) in blood donors in whom WNV infection was identified by WNV

180 Selected units were sourced from blood donors included in the British Bone Marrow Registr

181 d increase in overall mortality among former blood donors, including significantly increased mortalit

182 ort for the first time an asymptomatic human blood donor infected with B. clarridgeiae, as documented

183 The detection of hepatitis B virus (HBV) in blood donors is achieved by screening for hepatitis B su

184 iated mutations (DRMs) among treatment-naive blood donors is critical for monitoring viral evolution

185 re on how to find, recruit and maintain rare blood donors is not overwhelming, there are quite a few

186 ections in the English population (including blood donors) is unknown, but is probably widespread, an

187 oviral therapy (ART) use among South African blood donors led us to verify EC status.

188 vian Donations and Transfusions) database of blood donors linked with other nationwide health data re

189 globulin G (IgG) and IgM among 10,569 French blood donors living in mainland France and three oversea

190 tive cause) were investigated for peripheral blood donor lymphocyte macrochimerism.

191 and sera obtained from healthy, HBV-negative blood donors (n = 20).

192 ntravenous gamma globulin (n = 13) or normal blood donors (n = 20).

193 the assay, serum samples were assembled from blood donors (n = 372), acute hepatitis E patients (n =

194 men (n = 281), and seroprevalence surveys of blood donors (n = 457).

195 -seropositive healthy adults but not in cord blood donors (n = 5).

196 in two animal facilities and age/sex-matched blood donors (n = 63) as controls were tested for IgG an

197 udy, HIV patients (n = 457) and HIV-negative blood donors (n = 79) presenting to an HIV clinic in Gha

198 ischemic heart failure (n=141), and healthy blood donors (n=270).

199 1E-heterozygous than TACI-sufficient Swedish blood donors never immunized with pneumococcal antigens.

200 In this healthy population of blood donors, non-O blood groups explain >30% of venous

201 3.1% among personnel compared to 3.2% among blood donors; none were positive for IgM anti-HEV or HEV

202 The HIV viral diversity among blood donors observed in this study suggest that ongoing

203 HLA transfusion-specific antibodies (TSA) to blood donors of transfusions given posttransplant and ex

204 A total of 244 blood donors of transfusions received by 86 transplant p

205 es sampled from four self-limited cases, one blood donor, one fatal adult case, and one newborn with

206 assessed whether HIV incidence in first-time blood donors or associated transfusion risk increased.

207 n Europe may not optimize the gifts of whole-blood donors or minimize healthcare costs.

208 ted compared to 6.4% (16/250) observed among blood donors (OR, 1.3; CI, 0.41 to 4.0; P = 0.43).

209 rates were not elevated compared to those of blood donors (OR, 2.0; 95% CI, 0.10 to 122.9; P = 0.50).

210 was low, 4.0% (2/50), and similar to that of blood donors (P = 0.46; odds ratio [OR], 1.4; confidence

211 (HCV) infection due to large numbers of paid blood donors (PBD), injection drug users (IDU), and sexu

212 luated 500 seropositive and 300 seronegative blood donor plasma samples.

213 Blood donor plasma viremia status was first determined w

214 ymized samples were representative of the US blood donor population (n = 5000), healthy UK donors (n

215 rt of 64 individuals selected from a healthy blood donor population.

216 Targeting blood donor populations most likely to have influenza in

217 H1N1 influenza viremia (via RNA testing) in blood donor populations using multiple sensitive detecti

218 In blood donors, primary immune responses of low and/or hig

219 ificant research has focused individually on blood donors, product preparation and storage, and optim

220 undant evidence that leukocyte antibodies in blood donor products are somehow involved in transfusion

221 Nucleic acid testing (NAT) of blood donors provides opportunities for identifying West

222 Observations of MBL in blood donors raise concern that transmitted MBL may caus

223 ope mismatches and pretransplant, peripheral blood, donor-reactive IFN-gamma ELISPOT assay results co

224 and subsequently addressed through improved blood donor recruitment programs.

225 nly 52.4% of SARS-CoV-2 seropositive retired blood donors reported having been sick since the start o

226 Of blood donors reporting ILI symptoms postdonation, 1 of 1

227 healthy middle-aged and eight healthy older blood donors representing an average age difference of a

228 dependence on recruiting and retaining young blood donors requires a committed approach to donor safe

229 itch regions of memory B cells from European blood donors revealed frequent templated inserts origina

230 In 130 blood donors sampled during 2012 in Jeddah and 226 slaug

231 E1 and/or NS5B sequences from 411 volunteer blood donors sampled in 17 provinces and municipalities

232 Second, blood donor samples from infection-nonreactive, 18- to 4

233 ctivity to 15 other viruses tested or to 420 blood donor samples from the WNV pre-epidemic season.

234 Improvements in blood donor screening have decreased transfusion-associa

235 ly detect XMRV/MLV in blood samples and that blood donor screening is not warranted.

236 ing of blood from non-outbreak areas until a blood donor screening test becomes available have been i

237 es included antenatal care clinic screening, blood donor screening, HIV/STI bio-behavioural surveys,

238 ch were found both in meningioma and healthy blood donor sera.

239 Evidence regarding associations of blood donor sex with mortality among red blood cell tran

240 human CTL line from a normal healthy HLA-B7+ blood donor specific for this peptide.

241 mice that were pretreated with C57BL/6 (B.6) blood (donor-specific transfusion, DST) and nondepleting

242 onger incubation times were observed for the blood donor spleen inoculum compared with the blood dono

243 Randomized, nonblinded clinical trial of blood donors stratified by ferritin level, sex, and age

244 ut none of the 30 serum samples from healthy blood donors, suggesting its potential application as an

245 t with 30 control serum samples from healthy blood donors, suggesting their potential application for

246 EV between the at-risk group and age-matched blood donors suggests low transmission risk with univers

247 specific responses in 15 of 30 indeterminate blood donors tested, compared with none in controls (p=0

248 xposed individuals, but none of the European blood donors tested, have high levels of LAIR1-containin

249 rotein expression in macrophages from 7 of 9 blood donors tested.

250 conclusion, MBL prevalence is much higher in blood donors than previously reported, and although unco

251 raries was obtained from 12 HUE cases and 26 blood donors; the remaining HUE cases were sequenced as

252 d myeloid DC (mDC) from cord blood and adult blood donors to evaluate whether immunological immaturit

253 We use a convenience sample of blood donors to show that by June 2020, 1 month after th

254 strategies include matching RBC antigens of blood donors to those of transfusion recipients or provi

255 cytes (CTLs) generated from EBV-seropositive blood donors to treat patients with EBV-positive posttra

256 revention diagnostic criteria and 50 healthy blood donors, using a microarray with a cutoff fold diff

257 ed in 55 patients with CFS/ME and 75 healthy blood donors, using quantitative polymerase chain reacti

258 ca, the prevalence of malaria parasitemia in blood donors varies from 0.6% to 50%.

259 m four populations with various risks, i.e., blood donors, Veterans Administration (VA) patients, you

260 In parallel, genomic DNA from the blood donor was amplified to generate the late proviral

261 al after receipt of a transplant from a cord-blood donor was at least as favorable as that after rece

262 C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.36%, but contemporary data on the pre

263 on of healthy United States Caucasian random blood donors was in Hardy-Weinberg equilibrium and CCR5D

264 Viral genetic variant distribution in blood donors was similar to that seen in high-risk US po

265 Plasma from healthy blood donors was tested by enzyme-linked immunosorbent a

266 Cord blood donors were 40 women, ages >/=18 years, who delive

267 All 36 blood donors were BG negative, and 13 of 15 candidemic p

268 ee different ART/PrEP prevalence analyses in blood donors were conducted.

269 generated in vitro from the same individual blood donors were exposed to 5 different pathogens, and

270 he TNFRII 196 M/R polymorphism, 79 volunteer blood donors were genotyped at this locus, by polymerase

271 All healthy blood donors were negative for XMRV proviral sequences.

272 ed from differentiating erythroid cells from blood donors were performed to determine the transcripti

273 Eight patients and three blood donors were positive mostly for two subgroups of t

274 nonuclear cells (PBMCs) from 35 WNV-infected blood donors were screened for virus-specific T cell res

275 lood mononuclear cells from 44 healthy human blood donors were tested for reactivity against HLA-matc

276 PBMC from 69 aviremic and 56 viremic blood donors were then analyzed for the presence of HCV

277 d 25-OH vitamin D were measured; 119 healthy blood donors were used as controls.

278 from HBsAg-seropositive patients and healthy blood donors were used to determine clinical sensitivity

279 Participants were whole blood donors who agreed to continue trial participation

280 Prospective samples were collected from 1004 blood donors who called their donation center within 3 d

281 and class II genes in 231 Chinese voluntary blood donors who had cleared HCV infection spontaneously

282 ood mononuclear cells (PBMC) of seropositive blood donors who had spontaneously or therapeutically cl

283 hese autoantibodies and rheumatoid factor in blood donors who later developed rheumatoid arthritis.

284 lopment and persistence were investigated in blood donors who made WNV RNA-positive (viremic) donatio

285 ence T-cell activation in seven of the eight blood donors who responded strongly to wild-type P99beta

286 A total of 738 volunteer blood donors who were positive for anti-hepatitis C viru

287 by ELISA in plasma samples from asymptomatic blood donors who were reactive for RNA from DENV (n = 71

288 ment and retainment of future generations of blood donors will be needed, and care will be necessary

289 between convalescents and uninfected healthy blood donors with a predominantly CD4+ T cell response.

290 Four plasma samples from blood donors with acute HIV-1 infection and one viral cu

291 Here, we show that in 32 blood donors with acute WNV infection, Tregs expanded si

292 Physicians may encounter blood donors with adverse events and should be familiar

293 pective cohort study among initially healthy blood donors with an index T cruzi-seropositive donation

294 ion of macrophages from patients and healthy blood donors with genetic variants in NLRP3 and CARD8 an

295 nd general health in non-anemic repeat adult blood donors with iron deficiency (ferritin <= 50 ug/L).

296 of ferritin and hemoglobin levels in repeat blood donors with low iron stores, yet had no effect on

297 Among blood donors with normal hemoglobin levels, low-dose iro

298 Samples from blood donors with resolved and chronic HCV infections ha

299 bout a 20% decrease in reactions among young blood donors, with the greatest benefit observed among t

300 rols, we obtained serum from 101 sex-matched blood donors within the same age range.